Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of depemokimab in severe eosinophilic asthma
jRCT2021220009Active, not recruiting
- Sponsor
- GSK
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of depemokimab in asthma, sponsored by GSK. Primary endpoints: Number of participants with adverse events and serious adverse events over 52 weeks and Number of participants with immunogenicity to depemokimab. Started Jul 2022; status: active, not recruiting.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2021220009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220009.